

Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: a 10-year real-world retrospective cohort study

Edmond Atallah^{1,2}, Sarah J. Welsh³, Brent O'Carrigan³, Ana Oshaughnessy⁴, Igboin Dolapo⁴, Andrew S. Kerr³, Joanna Kucharczak³, Colin Lee³, Colin Crooks^{1,2}, Amy Hicks⁵, Chenchu Ramu Chimakurthi⁵, Ankit Rao³, Hester Franks^{4,6}, Poulam M. Patel^{4,6}, Guruprasad P. Aithal^{1,2}

¹Nottingham Digestive Diseases Centre, Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, UK.

²National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK.

³Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

⁴Department of Oncology, Nottingham University Hospitals NHS Trust, Nottingham, UK.

⁵Leeds Liver Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK

⁶Centre for Cancer Sciences, Translational Medical Sciences, Biodiscovery Institute, University of Nottingham, Nottingham, UK.

Corresponding author

Professor Guruprasad P. Aithal

Nottingham Digestive Diseases Centre, Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, UK

Email: guru.aithal@nottingham.ac.uk

Abstract: 275 words

Manuscript: 6857 words

Table: 5

Figures: 3

Supplementary materials: 7 Tables, 4 Figures

Financial support

The authors received no financial support to produce this manuscript.

Disclosures:

GP Aithal has received consulting fees from Pfizer, GlaxoSmithKline, Clinicpace, Servier Pharmaceuticals, NuCANA Plc, AstraZeneca and BenevolentAI paid to the University of Nottingham. All authors declare no conflicts of interest that relate to this work.

Data Transparency Statement

The data that support the findings of this study are available on reasonable request to the corresponding author.

Acknowledgements

We would like to thank the oncology specialist nurses at NUH, Yvette Moore and Joyce Ntata, who prospectively collected data on patients receiving checkpoint inhibitors.

Authors contributions

The manuscript was prepared and written by EA and revised by GPA. Statistical analyses were performed by EA and CC. AO, ID, AH, JK, CL and ASK contributed to data collection. SJW, BO, CRC, AR, HF and PMP contributed to the text of the manuscript. All authors have reviewed and approved the final submitted manuscript.

Abbreviations

ALP, alkaline phosphatase

ALT, alanine aminotransferase

AST, aspartate aminotransferase

ChILI, checkpoint inhibitor-induced liver injury

CI, confidence interval

CPI, checkpoint inhibitors

CTCAE, common terminology criteria for adverse events

CTLA4, Cytotoxic T lymphocyte associated molecule 4

CUH, Cambridge University Hospitals NHS Foundation Trust

DILI, drug-induced liver injury

EWG, expert working group

IR, incidence rate

irAE, immune-related adverse events

IQR, interquartile range

LTHT, Leeds Teaching Hospitals NHS Trust

LPS, lipopolysaccharide

NLR, neutrophil to lymphocyte ratio

NUH, Nottingham University Hospitals NHS Trust

OR, odds ratio

PD1, programmed cell death receptor 1

RCC, renal cell carcinoma

RUCAM, Roussel Uclaf causality assessment method

SD, standard deviation

TB, total bilirubin

ULN, upper limit of normal

Keywords

Checkpoint inhibitors, immunotherapy, immune-mediated hepatitis, hepatotoxicity, drug-induced liver injury, incidence rate, risk factors

Highlights

- Risk of checkpoint inhibitor-induced liver injury (ChILI) in real-world is higher than previously reported.
- In patients receiving combination therapy regime, the risk of new onset ChILI beyond four and half months of therapy is minimal.
- Female sex, lower baseline ALP and higher ALT are independent factors associated with increased risk of ChILI.
- Severity of ChILI using DILI criteria is lower than that estimated by the CTCAE criteria used in oncology.
- Rechallenge following ChILI is feasible; less than 10% develop recurrent liver injury that meet DILI criteria.

Abstracts

Background and Aims: Checkpoint inhibitors (CPI) are accounting for increasing number of drug-induced liver injury (DILI) cases. We aimed to determine the incidence rate and risk factors associated with checkpoint inhibitor-induced liver injury (ChILI).

Method: Prescription event monitoring was performed on all melanoma and renal cancer patients who received CPI at a tertiary centre between 2011 and 2021. ChILI cases were identified using the definitions, grading and causality assessment methods validated for DILI. We assessed risk factors associated with ChILI in CPI-naïve patients using multivariable logistic regression model. Consecutive patients with suspected ChILI from two other tertiary centres were adjudicated and combined for case characterization and outcomes of ChILI.

Results: Out of 432 patients received CPI over 10 years, ChILI occurred in 38 (8.8%) with an overall incidence rate of 11.5 per 1,000 patient-months (95% CI 8.2-15.8). Probability of ChILI was highest in combination therapy (32%) with no new events occurred beyond 135 days of treatment. Risk factor analysis showed that combination therapy, female sex, higher baseline alanine transferase level and lower baseline alkaline phosphatase level were independently associated with higher risk of ChILI. In total, 99 patients were adjudicated to have ChILI from three centres. Although Common Terminology Criteria for Adverse Events (CTCAE) classified 20 patients (20.2%) to have 'life-threatening' grade 4 hepatitis, ChILI severity was graded as mild in 45 (45.5%) and moderate in the remaining 54 (54.5%) cases.

Conclusion: The risk of ChILI in real-world is higher than previously reported. Among patients receiving dual CPI, this risk falls markedly after four and half

months. As CTCAE overestimates its clinical severity, case-definition, evaluation and management of ChLI should be revised to harmonise care.

Impact and implications

- Using prescription event monitoring over a 10-year period, the incidence rate of checkpoint inhibitor induced liver injury (ChILI) based on established case definitions for drug-induced liver injury (DILI) is 11.5 per 1,000 patient-months.
- Formal causality assessment has identified alternative cause in 19% of patients with suspected ChILI highlighting the importance of systematic evaluation by clinicians to minimize unnecessary immunosuppression.
- Intensity of monitoring in patients receiving combination therapy regime after four and half months of therapy can be reduced as the risk of new onset ChILI beyond this point is minimal.
- Current Common Terminology Criteria for Adverse Events (CTCAE) grading overestimates clinical severity of ChILI and hence contributing to avoidable hospitalization.

Background

The use of checkpoint inhibitors (CPI) has increased exponentially following their remarkable efficacy improving survival in many advanced malignancies. In patients with advanced melanoma or renal cell carcinoma (RCC), treatment with CPI targeting programmed cell death protein 1 (PD1) (e.g., nivolumab, pembrolizumab) as monotherapy or in combination with anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) (ipilimumab with nivolumab) are now established as standard of care (1-3). With their adoption as an effective therapy for advanced cancers, a range of immune-related adverse events (irAE) affecting different organs have also emerged.

Checkpoint inhibitor-induced liver injury (ChILI) is one of the important irAE following checkpoint blockade (4). Among fatalities reported in patients receiving anti-PD1 or anti-PD-ligand therapy, 22% (77/333) were attributed to 'hepatitis' (5). CPI are accounting for increasing proportion of drug-induced liver injury (DILI) cases in recent cohort studies (6, 7). While published studies have used the definition and grading based on the Common Terminology Criteria for Adverse Events (CTCAE), a standardised toxicity grading system widely accepted in clinical trials of cancer therapy (8, 9), this system was developed prior to the era of immunotherapy and there are limitations to its applicability for immunotherapy and irAE (10). The CTCAE classifies all organ system toxicities by severity grades 1 to 5 (grade 1 is mild, grade 2 is moderate, grade 3 is severe or medically significant, grade 4 refers to life-threatening and grade 5 refers to a fatal toxicity). For hepatic toxicity, these grades do not reflect clinical severity; for example, 20-fold elevation of either alanine aminotransferase (ALT), aspartate aminotransferase (AST), or alkaline phosphatase (ALP) alone is classified as life-threatening (grade 4) hepatitis without evidence of

any hepatic functional impairment such as jaundice, coagulopathy, ascites or encephalopathy. In addition, these events have not been assessed using validated causality assessment methods used for DILI. A recent study evaluated 70 events of liver injury identified based on liver biochemistry among 491 patients on pembrolizumab and adjudicated only 20 (28.6%) of these as ChILI (11). Therefore, identification and formal evaluation of suspected ChILI using the definition, severity grading and causality assessment using validated tools should form a basis for clinical practice guidance for the management of patients receiving CPI (12).

The incidence of ChILI has been reported using incidence proportion (risk) which varies widely in the literature. The overall risk of CTCAE grade 3 and 4 liver toxicity reported in clinical trials ranges from 0.6 to 16% depending on cancer and CPI regime or dose (4, 13). In systematic reviews of randomized trials of CPI, the reported pooled risk of \geq grade 3 hepatotoxicity following anti-CTLA4 and anti-PD1 was 3.3% and 9% (9, 14). However, retrospective studies reported much higher rates, 23.1% of all patients receiving CPI (15), and 21-33% of melanoma patients receiving combination therapy (16, 17). Incidence proportion uses the number of patients starting CPI at the start of study as a denominator, it does not consider the difference in durations of exposure to CPI between patients which varies significantly in clinical practice. In contrast, the incidence rate takes the number of patients and their time at risk into account and is considered a more accurate epidemiological method of event frequency, especially in dynamic populations with long follow-up. To date, no studies have defined ChILI and graded its severity according to DILI definitions or accurately assessed its incidence risk per person-time according to cancer type and CPI regime.

There is also limited data on risk factors that increase or decrease the development of ChILI during CPI therapy. Although recent studies showed that some clinical characteristics and baseline blood profile may predict immune-related adverse events and clinical outcomes following CPI (18-20), and represent possible risk factors of hepatotoxicity following CPI (17, 21), formal association between risk factors and ChILI have not been investigated using multivariable modelling.

We aimed to calculate the risk, incidence rate and cumulative incidence of ChILI in patients with melanoma and renal cell carcinoma (RCC) receiving CPI over a 10-year period. We have identified risk factors associated with ChILI occurrence in CPI-naïve patients. We have also characterised ChILI cases from three centres and reported their clinical outcomes of rechallenge.

Methods

Patient populations

All patients with malignant melanoma or advanced RCC who received at least one cycle of CPI (without concurrent chemotherapy or other targeted therapy) at Nottingham University Hospitals (NUH) from 2011 to June 2021 were included and categorised into seven subgroups based on cancer and CPI regime received. The project was registered at NUH, and patient informed consent was waived (21-375C). To characterise ChILI, compare severity grading between CTCAE and DILI definitions as well as describe outcomes of ChILI including rechallenge, we combined the cases from NUH with consecutive ChILI cases from two other UK tertiary centres. Consecutive patients with melanoma or RCC who received same regimes and developed possible ChILI at Cambridge University Hospitals NHS

Foundation Trust (CUH; study approval: ID4376/ PRN10376) between October 2014 and February 2021 and Leeds Teaching Hospitals NHS Trust (LTHT; study approval: ICI) between January 2018 and December 2021 were identified and underwent adjudication.

Outcomes and definitions

The primary outcome was ChILI occurrence which was defined and graded following the expert working group (EWG) definitions in DILI (12). ChILI cases were also graded following CTCAE version 5.0 to compare the risk and severity between the two grading systems (8). Because some patients who developed CTCAE grade 2 liver toxicity might meet EWG criteria and it is the threshold used to withhold CPI and consider corticosteroids, comparison of risk was made between EWG criteria and CTCAE grade ≥ 2 liver toxicity. Supplementary Table 1 highlights the thresholds used to define CTCAE grades of hepatotoxicity in comparison to EWG criteria. The ULN was defined using laboratory cut-offs. In the case of abnormal baseline liver enzymes, the definitions were adjusted to reflect change relative to the baseline rather than the ULN. Jaundice was defined as an elevation of total bilirubin (TB) $\geq 2 \times \text{ULN}$ at any time point during the liver injury and cases who met Hy's law (ALT $\geq 3 \times \text{ULN}$ and TB $\geq 2 \times \text{ULN}$) were identified (22).

All patients with suspected ChILI underwent formal causality assessment using the Roussel Uclaf Causality Assessment Method (RUCAM) (23) followed by an adjudication process. Patients who developed liver injury that was likely due to alternative aetiology or had insufficient investigations were excluded. For ChILI cases that passed adjudication, time to occurrence from start of CPI, rate of hospitalisation, other concurrent irAE (occurred during the time of liver injury),

investigations including histological features, treatment of ChILI, reported clinically significant side effects specific to steroid treatment, time to resolution (defined as normalisation of liver enzymes or return to baseline), and time to improvement to grade ≤ 1 CTCAE were recorded. Details of rechallenge following ChILI including regime used and outcomes were described. Recurrence of liver injury was defined based on the same EWG criteria used to define ChILI (12).

Prescription event monitoring to determine the risk and incidence rate of ChILI

All melanoma and RCC patients who received CPI at NUH from 2011 till June 2021 were identified using the prospective oncology prescribing database “Chemocare”. Liver enzymes were collected prior each cycle during CPI treatment and monitored for a minimum of 3 months after stopping CPI or till December 2021. The risk of ChILI (incidence proportion) in each CPI regime was calculated by dividing the number of patients who developed ChILI by the total number of patients who received the CPI. The 95% confidence interval for the proportion was calculated using the Wilson Score method (24, 25).

To determine the incidence rate of ChILI, the time at risk for each patient was estimated. For ChILI cases, time to event was the duration from the start of CPI regime until they met the predefined ChILI thresholds. For patients who did not develop ChILI, time at risk was defined as the duration of exposure to the specified CPI regime with latency ranges from 21 to 42 days after the last cycle, depending on the CPI regime (21 days for ipilimumab monotherapy, 28 days for nivolumab monotherapy or in combination with ipilimumab and 42 days for pembrolizumab). The duration at risk after the last CPI cycle was based on CPI regime frequency and the available literature on the clinical pharmacokinetics and pharmacodynamics of

CPI (26). The total person-time at risk in each subgroup was computed as person-months. The incidence rate of ChILI was estimated by dividing the number of ChILI events in each subgroup by the total patient-months at risk, and 95% confidence interval was calculated based on Byar's method (27, 28). The cumulative incidence (probability) of ChILI in each class of CPI was estimated using Kaplan–Meier method and cumulative incidence function.

Case-control study to identify risk factors associated with ChILI

Patients who were adjudicated as ChILI from NUH were defined as cases; those who received CPI without developing ChILI were included in the control group. We investigated risk factors of ChILI in CPI-naïve patients (receiving CPI for the first time) only, those who had CPI previously were excluded from the analysis.

Haematology and liver profiles prior to starting CPI and clinical characteristics including age, sex, body mass index (BMI), cancer type, CPI regime and presence of liver metastases at baseline were obtained. Peripheral blood count data included absolute count of neutrophils, lymphocytes and eosinophils, and neutrophil-to-lymphocyte ratio (NLR).

Statistical methods

Demographic and clinical data were described using descriptive statistics, mean \pm standard deviation (SD) for continuous measurements that are normally distributed, median and interquartile range (IQR) or full range when more appropriate for non-normally distributed continuous variables. Frequencies and percentiles were used for categorical data. Differences in baseline characteristics between patients who developed ChILI and patients without ChILI were evaluated using the Student's T-test of the continuous variables, or Pearson Chi-squared test for proportions, as

appropriate. Continuous variables exhibiting a skewed distribution were transformed, using the natural logarithms, before t-tests were conducted to satisfy the prerequisite assumptions of normality. Mann-Whitney-Wilcoxon test was applied if variables were not normally distributed despite transformation. Kruskal-Wallis one-way analysis of variance was used to assess difference of median duration of resolution of liver injury or improvement to grade 1 CTCAE between CPI classes.

To study the association between baseline blood profile and clinical characteristics with ChILI, multivariable logistic regression analysis was performed on the NUH cohort. Variables with significant difference between cases and controls were included in the final model. Age, sex, CPI regime and presence of liver metastases at baseline were considered as priori confounders and included in the final model. Odds ratios (OR) were calculated and $P < 0.05$ was considered significant. All analyses were conducted using R programme version 4.0.3 (29). R packages used to estimate cumulative incidence were “survival”, “etm” and “cmprsk” (30-32).

Results

Risk, incidence rate and cumulative incidence of ChILI

Over 10 years, a total of 432 patients received CPI at NUH, 359 patients with melanoma and 73 with RCC. None of the patients treated had underlying autoimmune liver disease. Fifty (11.6%) out of 432 patients had elevated ALT > ULN before starting CPI. These were investigated based on the risk factors, 15 were attributed to liver metastases and 3 to non-alcoholic fatty liver disease. After the first cycle of CPI, liver enzymes normalised in 23 patients (46%). The remaining 9

patients had negative viral serology and autoantibody profile. Details of frequency and dose of CPI regimens are shown in Supplementary Table 2. 47 patients (10.9%) had acute liver injury and met the EWG criteria. However, nine out of 47 (19.1%) were excluded following causality assessment and adjudication process (seven had progressive liver metastases, one had biliary obstruction/cholangitis and one had idiosyncratic DILI). The predominant pattern of liver injury in excluded cases was cholestatic, seven out of nine cases. Overall, 38 patients developed ChILI (8.8%). On causality assessment ChILI were classified as possible in 9 (23.7%), probable in 22 (57.9%) and highly probable in 7 (18.4%). The median RUCAM score was 7 (probable). The risk of ChILI varied among CPI regimens with the highest risk occurring in melanoma patients who received combination therapy followed by anti-PD1 (28.4%), Figure 1. In contrast, the risk of CTCAE grade ≥ 2 liver toxicity was 10.4% overall and 32.4% in melanoma patients on dual CPI therapy.

The overall incidence rate of ChILI was 11.5 per 1,000 patient-months. The highest incidence rate was in melanoma patients receiving a combination of ipilimumab and nivolumab (38.1 per 1,000 patient-months). Incidence rates of ChILI per CPI regimen are shown in Table 1. The shortest latency to ChILI occurrence was observed in melanoma and renal patients who received combination therapy, median latency was 51 days (range 17 to 135 days). In contrast, the median latency to ChILI in patients who received anti-PD1 monotherapy was 106 days (range 70 to 526 days). We limited the cumulative incidence estimation of ChILI to one year because the number of patients at risk beyond one year of CPI therapy was small. In patients with melanoma and renal combined, the highest cumulative incidence (probability) of ChILI was in combination therapy, 32.1%, with no ChILI events occurred after 4 and half months from starting CPI, Figure 2 and Supplementary Table 3. In patients who

received monotherapy of anti-CTLA4 or anti-PD1, the probability of developing ChILI over 1 year was 2.9% and 2.5%, respectively, as shown in Figure 2 and Supplementary Tables 4 and 5. There was one late ChILI occurrence in a patient who received anti-PD1 monotherapy after 526 days.

Risk factors associated with ChILI in CPI-naïve patients

Analysis of risk factors for patients who were treated at NUH over 10 years with no previous exposure to CPI included 36 ChILI cases and 358 controls. Clinical characteristics, baseline blood and liver profile of cases and controls are summarized in Table 2. Patients who developed ChILI were younger ($p=0.002$), more likely to have received combination therapy ($p<0.001$), had significantly higher baseline ALT ($p=0.003$), lower ALP ($p=0.01$), lower neutrophils ($p=0.03$) and lower NLR ($p=0.008$). There was no significant difference in the type of cancer, BMI, presence of liver metastases, baseline lymphocytes or eosinophils between the groups. Patients with liver metastases had multiple liver lesions throughout the liver rather than solitary lesion. In multivariate logistic regression analysis, independent risk factors associated with ChILI were combination CPI followed by anti-PD1 regime (OR 10.95; 95% CI 4.04-35.6, $p<0.001$), female sex (OR 2.54; 95% CI 1.09-6.06, $p=0.032$), baseline ALT (1.03; 95% CI 1.01-1.05, $p=0.006$) and ALP (0.99; 95% CI 0.98-1.00, $p=0.015$), Table 3.

Pattern and severity of ChILI cases from three centres

Consecutive patients with malignant melanoma or renal cancer with suspected ChILI at CUH and LTHT were identified and considered for inclusion. 25 out of 30 from CUH and 36 out of 38 from LTHT passed adjudication. A summary of the

investigations performed to exclude alternative causes and used in adjudication are shown in Supplementary Table 6. Clinical characteristics of adjudicated ChILI cases from three centres are summarised in Table 4, and details of suspected cases who did not pass adjudication are summarised in Table 5. The Median RUCAM score was 7 for CUH and 8 for LTHT (probable). Among the 99 ChILI cases from three centres who passed adjudication, the pattern of liver injury was hepatocellular in 53 cases (53.5%), mixed in 29 (29.3%) and cholestatic in 17 (17.2%), as shown in Table 4 and Figure 3. Severity grading was mild in 45 cases (45.5%) and moderate in the remaining 54 (54.5%). Out of 99, 10 patients developed jaundice and met Hy's law (10.1%), the pattern of liver injury was hepatocellular in 4, mixed in 3 and cholestatic in 3. However, none of the cases was severe as per EWG criteria. When compared to CTCAE criteria, 20 out of 99 ChILI cases (20.2%) were classified as grade 4 (life-threatening; urgent intervention indicated), 78 (78.8%) as grade 3 (severe or medically significant but not immediately life-threatening) and 1 (1%) as grade 2 (moderate), Table 4 and Figure 3.

Treatment of ChILI, resolution and association with other irAE

Out of 99 patients who developed ChILI from three centres, only four patients did not receive corticosteroids (4%). Furthermore, out of 16 patients who were suspected to have ChILI but had alternative aetiology after investigations, 13 were empirically treated with corticosteroids (81%). 51 patients out of 99 were hospitalised following oncology guidelines (51.5%). All hospitalised patients received corticosteroids, most received IV methylprednisolone, 38 out of 51 patients (74.5%). The rest of hospitalised patients received oral prednisolone; the dose varied from 50 to 225 mg once daily. 21 out of 99 patients received second line immunosuppression (21.3%),

15 had mycophenolate mofetil (MMF) and six patients received MMF plus tacrolimus. There was obvious variability in management strategies between centres, as highlighted in Table 4. Nine out of 99 patients underwent liver biopsy as part of investigations and the histological features were consistent with ChILI. Five out of 36 ChILI cases who received steroids at NUH (13.9%), had clinically significant side effects related to corticosteroid therapy; two developed diabetes, two developed myopathy and one had a severe acneiform rash. Steroid-related adverse events were not recorded at other centres.

The median time to resolution of ChILI in patients treated with steroids was 67 days (range 11-550) and time to first liver enzymes \leq grade 1 CTCAE was 21 days (range 2-133). In the four patients untreated with steroids, median time to resolution was 34 days (range 28-63) and time to first liver enzymes \leq grade 1 CTCAE was 24 days (range 15-28). The difference in time to resolution and to \leq grade 1 CTCAE toxicity was not statistically significant between CPI classes, Supplementary Figures 1-4. Among patients with ChILI, 58 developed other concurrent irAE (58.6%). Thyroiditis and colitis were the most common occurring in 20 patients (20.2%) followed by skin rash in 14 (14.1%), adrenalitis in 9 (9.1%) and hypophysitis in 5 (5.1%), Table 4.

Outcome of rechallenge

Rechallenge was performed in 37 out of 99 patients (37.4%), 31 of those had ChILI following combination therapy, four following pembrolizumab and one each after nivolumab monotherapy and ipilimumab monotherapy. 35 patients received anti-PD1 monotherapy as rechallenge CPI regime, one had ipilimumab monotherapy and one had combination therapy. Details of CPI regimes used in rechallenge and recurrence are summarised in Supplementary Table 7. Three patients were taking

immunosuppression at the time of rechallenge (oral prednisolone 10-25 mg), one as prophylactic measure for ChILI, one was on steroids tapering regime and one received it for previous CPI-induced pneumonitis.

Seven patient developed elevation of liver enzymes on rechallenge (21.6%). Three patients met EWG criteria (8.1%) which was defined as recurrence of ChILI. Four patients developed grade 2 hepatotoxicity that did not meet DILI criteria and CPI was permanently stopped (ALT elevation 3-5 folds without rise in bilirubin). Nine patients developed other clinically significant irAE requiring hospitalisation or treatment (24.3%); five had colitis, two had hypophysitis, one had severe neuropathy and one had skin toxicity.

Discussion

We have established the risk, incidence rate and cumulative probability of checkpoint inhibitor-induced liver injury (ChILI) in patients with malignant melanoma or advanced RCC, per cancer and CPI regime in a real-world cohort over 10 years. All ChLI cases were defined and graded using DILI EWG recommendation as well as formally adjudicated following causality assessment (12), (23). The overall risk of ChILI was 8.8% and the incidence rate was 11.5 per 1,000 patient-months. The highest risk and incidence occurred in patients with melanoma receiving a combination of anti-CTLA4 and anti-PD1, 28.4% and 38.1 per 1,000 patient-months, respectively. Therefore, the risk of ChILI in clinical practice even when stringent criteria applied is higher than previously reported in clinical trials (9, 14). Patients with melanoma are the most common group to be affected by ChILI and this is explained by the fact that they frequently receive combination CPI therapy. Combination therapy has been associated with higher frequency of hepatotoxicity in clinical trials and Dutch national registry (2, 9, 17, 33). Overall risk of ChILI of 8.8% among those treated with CPI is remarkably high when compared with an estimated incidence of amoxicillin-clavulanate DILI (a common aetiology) of 0.16% among those exposed to the drug (34). The magnitude of difference in the incidence of DILI and ChILI may well be related to the underlying mechanism. Genetic and experimental medicine studies that have investigated DILI support the 'hapten mechanism' where MHC class II and I restricted CD4⁺ and CD8⁺ clones are activated by a drug-derived antigen (35). We have recently identified a distinct population of circulating effector memory CD8⁺ cells in patients during an acute phase of ChILI (36). CPI act upon T cell surface receptors as their therapeutic target which may explain in part the high incidence of immune related adverse events such

as ChILI. Although rs16906115 near *IL7* locus has been associated with immune related adverse events in a genome wide association study (37), the variant hasn't been associated with liver related adverse events in particular. Robust case definitions and causality assessments are essential to identify risk factors for ChILI.

The cumulative probability of ChILI in patients who received combination therapy followed by anti-PD1 was 32% with a median latency of 51 days from the start of CPI. ChILI occurred as early as 17 days after the first cycle of ipilimumab and nivolumab, with no new events noted beyond 135 days for patients who continued nivolumab monotherapy. This data indicates that in this group of patients, the risk of ChILI falls in the later phase of treatment and therefore intensity of monitoring may be reduced accordingly. In contrast, in patients who received anti-PD1 monotherapy (nivolumab or pembrolizumab), ChILI developed after a median of 106 days, with one patient developing ChILI after one year of exposure. Interestingly, the cumulative probability of ChILI following anti-CTLA4 was similar to anti-PD1 (2.9% compared to 2.5%) contrary to previous suggestions (13).

We assessed risk factors associated with ChILI occurrence in CPI-naïve patients. CPI regime, female sex and baseline ALP and ALT were significant independent risk factors associated with ChILI. Patients starting combination therapy with anti-CTLA4 and anti-PD1 have a significantly increased risk of ChILI compared with patients receiving anti-PD1 monotherapy, this is consistent with previous studies (4). Furthermore, women were almost three times more likely to develop ChILI than men. In recent study that involved 877 patients of patients undergoing CPI, women had 54% increased risk of symptomatic adverse reaction (20). In another study of 1096 patients treated with CPI, liver toxicity was significantly more common in women

(21); however, multivariable modelling was not performed to confirm independent association. Sex differences in efficacy, toxicity and increased susceptibility of women to toxicity from chemotherapy in particular have been observed before (38). However, whether these are due to differences in tumour biology or pharmacokinetics/ pharmacodynamics of CPI are yet to be elucidated. Further understanding of the impact of sex on CPI therapy and irAE is needed (20, 38).

An increase of baseline ALT was a risk factor for the development of ChILI; a similar observation was made in a recent study of anti-tuberculosis DILI (39). Intriguingly, higher baseline ALP was associated with reduced ChILI occurrence. Although these two associations might not be clinically significant, they may reflect important mechanistic associations. In a mice model, ALP protected the animal from acute liver injury induced by delayed-type hypersensitivity (40). It has also been shown that ALP is able to detoxify lipopolysaccharide (LPS) derived from the gut-portal axis by removing the terminal phosphate group, thus limiting LPS-mediated liver injury (41, 42). Further research is needed to explore the potential mechanisms by which intestinal microbiota influences susceptibility to ChILI (43).

Age and presence of liver metastases at baseline were not independent risk factor of ChILI, which is consistent with previous studies (17, 44). A retrospective cohort showed that the incidence of all grade liver toxicity is highest in patients 50-64 years old (10.6%) compared to 3.1% in 65-74 age group and 4.3% in the age group >74; however, the difference did not reach statistical significance (44). Another retrospective study reported a comparable proportion of liver metastases between patients with and without ChILI (17). Although baseline neutrophil-to-lymphocyte ratio (NLR) was significantly different between patients with and without ChILI, a

similar observation recently reported (21), it was not independently associated with ChILI in multivariable analysis. This highlights the importance of using appropriate statistical models to evaluate independent associations.

We identified all patients who developed acute liver injury among those treated at NUH over 10 years. Of those who met the predetermined criteria, 89.4% (42 out of 47) started promptly on steroids for suspected ChILI. Nonetheless, 6 of those treated with steroids (14.3%) were found to have alternative explanation for liver biochemistry abnormalities. Furthermore, all patients with suspected ChILI from the other two centres who did not pass adjudication due to alternative aetiology after work up received empirical corticosteroids. It can be argued that both the interruption of CPI and introduction of steroids were not necessary in these patients. A similar yield of alternative diagnoses has been reported in multiple other studies (11, 45, 46). These observations stress the importance of careful evaluation of suspected ChILI and causality assessment prior to initiating steroid therapy as much as possible. Only 8% of ChILI cases with available antinuclear antibodies (ANA) had a positive result and only one patient had elevated level of serum IGG. Riveiro-Barciala et al. reported higher proportion of ANA positivity (32%) among ChILI cases but also reported one patient with raised IGG highlighting the difference in prevalence of autoantibodies in ChILI compared to autoimmune hepatitis (46).

In addition, a fifth of ChILI patients from three centres were classified as grade 4 CTCAE hepatotoxicity (life-threatening), while only 10% of all cases developed jaundice and none developed acute liver failure. Over half of patients were hospitalised as CTCAE recommends hospitalization in patients with hepatitis grade 3 and above (8). Rapid evaluation of patients with suspected ChILI ahead of initiation

of steroids should be considered. It is desirable that currently used definitions and grading of liver injury after CPI are revised in view of these findings.

European Society of Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO) guidelines recommend steroid therapy for \geq grade 2 hepatitis (47, 48). Vast majority (96%) of patients who developed ChILI from three cohorts received corticosteroids, similar to other studies (46). This reflects the current practice despite the growing evidence that some patients improve without the need for immunosuppression (49, 50). Corticosteroid therapy was associated with significant side effects that required medical attention in 13% of ChILI cases in our cohort. Steroid therapy in the management irAE has been shown to increase the risk of serious infections and osteopenia (51, 52). The number of ChILI cases who did not receive steroids was very small so no valid conclusions can be drawn regarding steroid use or duration to resolution of liver injury. Another study that compared patients with hepatotoxicity following CPI (based on CTCAE criteria) who received steroids (n=67) with those not receiving steroids (n=33) showed that median duration of improvement of ALT was significantly shorter in patients without steroids (50); there were no differences in any of the clinical characteristics observed between these two groups other than steroid therapy. In addition, there are multiple reports of liver injury attributed to corticosteroids themselves including oral prednisolone (53-55), and methylprednisolone (56). Furthermore, the use of second and third line immunosuppression varied significantly between centres despite no cases with acute liver failure. Therefore, future prospective studies involving large number of well-phenotyped cases of ChILI are needed to inform the optimum management of ChILI including risks and benefits of corticosteroids and other immunosuppressive drugs.

More than a third of patients with ChILI were rechallenged with anti-PD1 monotherapy being the most common CPI class used. 21.6% developed elevation of liver enzymes following rechallenge and CPI was stopped consistent with other studies (13, 50). However, only 8.1% met EWG criteria at time of recurrence of liver injury. Several prophylactic strategies have been proposed when considering rechallenging following irAE affecting other organs (57); however, there is limited evidence specific to hepatotoxicity. Further research is needed to investigate mechanisms, risk factors and possible effective prophylactic strategies to predict and avoid recurrence of ChILI.

Our study differs from previously published retrospective studies. Our cohort is homogenous and included two main cancer populations who receive CPI as standard of care without concomitant oncological treatments. We included all patients who received CPI over 10 years to enable accurate estimation of the frequency of ChILI and minimise selection bias. In another retrospective study that reported 28 patients from 15 different cancers who developed ChILI, 9 of them (32%) received concomitant oncological treatment in addition to CPI (46). To our knowledge, this is the only study that defined ChILI based on DILI criteria, systematically used prescription event monitoring method in a 10-year cohort and investigated independent associations in multivariable analysis of risk factors.

Despite its strengths, our study has some limitations. To calculate the incidence rate, the time at risk after stopping CPI, for patients who did not develop ChILI, was estimated based on CPI regime frequency and published data on the clinical pharmacokinetics and pharmacodynamics of CPI (26). However, this might underestimate the duration of T cell activation after stopping CPI which lasts beyond

the half-life of the CPI and varies between patients. Patients were followed up for a minimum of 90 days after stopping CPI. In a literature review that included 194 trials and 367 case reports and series from 2008-2018, the incidence of delayed ChILI presenting ≥ 90 days after discontinuation of immunotherapy was limited to one case over a period of 10 years (58). This is consistent with our findings too. All patients who were receiving CPI had a minimum of six-months exposure of CPI before the data collection cut off. We acknowledge that our risk factor model had small sample size and further validation in large independent cohort is desirable.

In conclusion, the overall incidence rate of ChILI in malignant melanoma and advanced RCC patients is 11.5 per 1,000 patient-months. Melanoma patients receiving combination therapy have the highest risk of ChILI; however, the risk of new-onset ChILI in melanoma and renal cancer patients who received combination therapy and continued on anti-PD1 drops after 4 and half months of therapy. Women and patients with low baseline ALP and high baseline ALT have an increased risk of developing ChILI. Delineation of the period at which adverse events appear during the course of CPI therapy, use of standardised criteria to define ChILI and structured evaluation using validated causality assessment would harmonise care of these patients.

Figure legends

Figure 1. Risk of ChILI per CPI regime in melanoma and renal cancer.

Risk of ChILI (incidence proportion) in each subgroup was calculated by dividing the number of patients who developed ChILI by the total number of patients who received the CPI regime.

Abbreviations: ChILI, Checkpoint inhibitor-induced liver injury; CPI, Checkpoint inhibitors; CTCAE, Common Terminology Criteria for Adverse Events V5.0 (8); EWG, Expert Working Group definitions in drug-induced liver injury (12); RCC, Renal cell carcinoma.

Figure 1. Probability of ChILI per CPI class over 1 year

Cumulative incidence (probability) of ChILI per CPI class was estimated using Kaplan–Meier method and cumulative incidence function using R programme.

Abbreviations: Anti-CTLA4: Anti-cytotoxic T-lymphocyte-associated protein 4; Anti-PD1: Anti-programmed cell death protein 1; ChILI: Checkpoint inhibitor-induced liver injury; CPI: Checkpoint inhibitors.

Figure 3. Pattern and severity of ChILI cases from three centres

The pattern of ChILI is based on the earliest identified liver chemistry elevations above the upper limit of normality (ULN) that meet ChILI criteria and defined using R-value where $R = (\text{ALT}/\text{ULN})/(\text{ALP}/\text{ULN})$. Hepatocellular ($R \geq 5$); Cholestatic ($R \leq 2$) and Mixed ($R > 2$ and < 5). Abbreviations: ChILI, Checkpoint inhibitor-induced liver injury; CTCAE: Common Terminology Criteria for Adverse Events V5.0 (8); EWG: Expert Working Group grading in drug-induced liver injury (12).

Tables

Table 1. Incidence rate of ChILI per CPI regime at NUH

Cancer	CPI regime	Total person-time at risk (months)	ChILI cases (N)	IR per 1000 patient-months	95% CI
Malignant Melanoma	Ipilimumab	200.5	2	10.0	1.2 - 36
	Ipilimumab + Nivolumab followed by Nivolumab	761.1	29	38.1	25.5 - 54.7
	Nivolumab	281.2	0	0	0 -13.1
	Pembrolizumab	1035.4	3	2.9	0.6 - 8.5
	Adjuvant Pembrolizumab	343.3	1	2.9	0.1 - 16.2
Advanced RCC	Ipilimumab + Nivolumab followed by Nivolumab	149.1	2	13.4	1.6 - 48.5
	Nivolumab	524.7	1	1.9	0 - 10.6
Total	All regimes	3295.3	38	11.5	8.2 - 15.8

Abbreviations: CPI, Checkpoint inhibitors; ChILI, Checkpoint inhibitor-induced liver injury; CI, Confidence interval; IR, Incidence rate; RCC, Renal cell carcinoma.

Table 2. Clinical characteristics and baseline blood profile of CPI-naïve patients at NUH

	All patients (n = 394)	Cases (n = 36)	Controls (n = 358)	P value
Age, years (Mean, SD)	65 (13)	57 (15)	65 (13)	0.002
Sex, n (Male, %)	255 (64.7)	20 (55.6)	235 (65.6)	0.23
BMI, kg/m² Median (IQR)	26 (23, 31.7)	25.5 (21.7, 31.2)	27 (23, 31.7)	0.48
Type of cancer, n (column %)				
Malignant melanoma	321 (81.5)	33 (91.7)	288 (80.4)	0.10
Advanced RCC	73 (18.5)	3 (8.3)	70 (19.6)	
Type of CPI, n (column %)				
Combination followed by anti-PD1	115 (29.2)	29 (80.5)	86 (24)	<0.001
Anti-CTLA4	83 (21.1)	2 (5.6)	81 (22.6)	
Anti-PD1	196 (49.7)	5 (13.9)	191 (53.4)	
Presence of liver metastases prior CPI, n (%)	61 (15.5)	5 (13.9)	56 (15.6)	0.78
ALT, IU (ULN: 45 males, 35 females) Median (IQR)	21 (14, 31)	27.5 (18, 39)	21 (14, 29)	0.003
ALP, IU (ULN: 130) Median (IQR)	92 (74, 124)	85 (71, 103.8)	94 (74.2, 126)	0.01
Total Bilirubin, umol/L (ULN: 21) Median (IQR)	9 (7, 12)	9 (7, 11.5)	9 (7, 12)	0.61
Neutrophils, x10⁹/L Median (IQR)	5 (3.9, 6.5)	4.4 (3.4, 5.8)	5 (4, 6.6)	0.03
Lymphocytes x10⁹/L Median (IQR)	1.6 (1.2, 2)	1.8 (1.2, 2.1)	1.5 (1.2, 2)	0.12
Neutrophil to lymphocyte ratio (NLR) Median (IQR)	3.1 (2.3, 4.8)	2.5 (2, 3.3)	3.2 (2.3, 4.9)	0.008
Eosinophils x10⁹/L Median (IQR)	0.1 (0.1, 0.2)	0.1 (0.1, 0.3)	0.1 (0.1, 0.2)	0.62*

P values were derived from Pearson's Chi-squared for categorical variables and Student's T-test for age or the natural logarithm of other continuous variables. * Mann-Whitney-Wilcoxon test was performed. Abbreviations: ALT, Alanine aminotransferase; ALP, Alkaline phosphatase; Anti-CTLA4, Anti-cytotoxic T-lymphocyte-associated protein 4; Anti-PD1, Anti-programmed cell death protein 1; BMI, Body mass index; ChILI, Checkpoint inhibitor-induced liver injury; CPI, Checkpoint inhibitors; IQR, interquartile range; RCC, Renal cell carcinoma; SD, standard deviation; ULN, Upper limit of normal. Baseline blood profile was unavailable from 4 controls.

Table 3. Factors associated with ChILI in CPI naïve patients (NUH cohort)

Factors		Unadjusted OR (95% CI)	Adjusted OR (95% CI)
Age		0.95 (0.93-0.98, p<0.001)	0.99 (0.95-1.02, p=0.38)
Female sex		1.53 (0.76-3.05, p=0.23)	2.54 (1.09-6.06, p=0.03)
CPI	Anti-PD1 (reference)	-	-
	Anti-CTLA4	0.94 (0.13-4.47, p=0.94)	0.65 (0.09-3.31, p=0.62)
	Combination followed by anti-PD1	12.88 (5.23-38.87, p<0.001)	10.95 (4.04-35.60, p<0.001)
Liver metastases		0.87 (0.29-2.15, p=0.78)	1.76 (0.45-6.25, p=0.39)
NLR		0.82 (0.65-0.97, p=0.05)	0.90 (0.72-1.05, p=0.28)
ALT		1.00 (0.99-1.01, p=0.30)	1.03 (1.01-1.05, p=0.006)
ALP		0.99 (0.98-1.00, p=0.08)	0.99 (0.98-1.00, p=0.01)

Univariable and multivariable logistic regression for ChILI occurrence. Number included in analysis = 394, number in model = 390, missing values = 4.

Abbreviations: ALT, Alanine aminotransferase; ALP, Alkaline phosphatase; Anti-CTLA4, Anti-cytotoxic T-lymphocyte-associated protein 4; Anti-PD1, Anti-programmed cell death protein 1; ChILI, Checkpoint inhibitor-induced liver injury; CPI, Checkpoint inhibitors; NLR, Neutrophil to lymphocyte ratio; OR, Odds ratio; ULN, Upper limit of normal

Table 4. Clinical characteristics of ChILI cases from three centres.

		NUH (n=38) 2011-2021	CUH (n=25) 2014-2021	LTHT (n=36) 2018-2021	Total (n=99)
Cancer, n (%)	Malignant Melanoma	35 (92.1%)	20 (80%)	32 (88.9%)	87 (87.9%)
	Advanced RCC	3 (7.9%)	5 (20%)	4 (11.1%)	12 (12.1%)
CPI regime in melanoma, n (%)	Ipilimumab + Nivolumab followed by Nivolumab	29 (82.9%)	11 (55%)	21 (65.6%)	61 (70.1%)
	Ipilimumab	2 (5.7%)	1 (5%)	0	3 (3.4%)
	Nivolumab	0	2 (10%)	2 (6.3%)	4 (4.6%)
	Pembrolizumab	3 (8.6%)	4 (20%)	6 (18.8%)	13 (14.9%)
	Adjuvant Pembrolizumab	1 (2.9%)	2 (10%)	3 (9.4%)	6 (6.9%)
CPI regime in RCC, n (%)	Ipilimumab + Nivolumab followed by Nivolumab	2 (66.7%)	2 (40%)	3 (75%)	7 (58.3%)
	Nivolumab	1 (33.3%)	3 (60%)	1 (25%)	5 (41.7%)
Previous exposure to CPI, n (%)		2 (5.3%)	3 (12%)	6 (16.7%)	11 (11.1%)
Previous exposure chemo/targeted therapy, n (%)		6 (15.8%)	7 (28%)	3 (8.3%)	16 (16.2%)
Median number of cycles prior to ChILI (IQR)		3 (2,4)	2 (1,3)	3 (2,4)	3 (2,4)
CTCAE hepatotoxicity grade, n(%)	2 (Moderate)	1 (2.6%)	0	0	1 (1%)
	3 (Severe)	28 (73.7%)	22 (88%)	28 (77.8%)	78 (78.8%)
	4 (Life-threatening)	9 (23.7%)	3 (12%)	8 (22.2%)	20 (20.2%)
EWG severity grade, n(%)	Mild	11 (28.9%)	18 (72%)	16 (44.4%)	45 (45.5%)
	Moderate	27 (71.1%)	7 (28%)	20 (55.6%)	54 (54.5%)
	Severe	0 (0%)	0 (0%)	0	0 (0%)
Developed jaundice (total bilirubin \geq 2 folds), n(%)		2 (5.3%)	2 (8%)	6 (16.7%)	10 (10.1%)
Pattern	Hepatocellular	22 (57.9%)	12 (48%)	19 (52.8%)	53 (53.5%)
	Mixed	11 (28.9%)	8 (32%)	10 (27.8%)	29 (29.3%)
	Cholestatic	5 (13.2%)	5 (20%)	7 (19.4%)	17 (17.2%)
Median RUCAM score (IQR)		7(6,8)	7 (5,8)	8 (7,9)	8 (6,8)
Treatment of ChILI, n(%)	Corticosteroids alone	34 (89.5%)	21 (84%)	19 (52.8%)	74 (74.7%)

	Corticosteroids + MMF	2 (5.3%)	2 (8%)	11 (30.6%)	15 (15.2%)
	Corticosteroids + MMF + Tacrolimus	0	0 (0%)	6 (16.7%)	6 (6.1%)
	None	2 (5.3%)	2 (8%)	0 (0%)	4 (4%)
Patients with concurrent other irAE, n(%)		22 (57.9%)	13 (52%)	23 (63.9%)	58 (58.6%)
Most common concurrent irAE, n(%)	Thyroiditis	15 (39.5%)	3 (12%)	2 (5.6%)	20 (20.2%)
	Colitis	8 (21.1%)	3 (12%)	9 (25%)	20 (20.2%)
	Skin rash	5 (13.2%)	3 (12%)	6 (16.7%)	14 (14.1%)
	Adrenalitis	0	1 (4%)	8 (22.2%)	9 (9.1%)
	Hypophysitis	1 (2.6%)	2 (8%)	2 (5.6%)	5 (5.1%)

Abbreviations: CPI, Checkpoint inhibitors; ChILI, Checkpoint inhibitor-induced liver injury; CPI, Checkpoint inhibitors; CTCAE, Common Terminology Criteria for Adverse Events V5.0 (8); EWG, Expert Working Group definitions and grading in drug-induced liver injury (12); irAE, immune-related adverse events; IQR, interquartile range; CUH, Cambridge University Hospital NHS Foundation Trust; LTHT, Leeds Teaching Hospitals NHS Trust; NUH, Nottingham University Hospitals NHS Trust; RCC, Renal cell carcinoma

Table 5. Characteristics of patients with suspected ChILI who were excluded after adjudication from three centres

Age and sex	Cancer, Liver metastasis prior CPI (Y/N)	CPI regime	Cycles prior liver injury	Pattern of liver injury	Received empirical steroids	Diagnosis, liver injury resolved (Y/N)	12 months clinical outcome
50 F	MM (Y)	Ipilimumab + Nivolumab	3	Mixed	Yes	Disease progression with widespread liver metastases (N)	Died of disease progression
51 F	MM (Y)	Ipilimumab + Nivolumab	3	Hepatocellular	Yes	Disease progression with widespread liver metastases (N)	Died of disease progression
66 M	MM (Y)	Ipilimumab	2	Cholestatic	Yes	Disease progression with widespread liver metastases (N)	Died of disease progression
76 F	MM (Y)	Ipilimumab	2	Mixed	Yes	Disease progression with widespread liver metastases (N)	Died of disease progression
37 M	MM (Y)	Ipilimumab	3	Cholestatic	Yes	Liver metastases causing biliary obstruction (N)	Died of disease progression
55 F	MM (Y)	Ipilimumab	1	Hepatocellular	Yes	Disease progression with widespread liver metastases (N)	Died of disease progression
50 M	MM (Y)	Ipilimumab	4	Cholestatic	No	Disease progression with widespread liver metastases (N)	Died of disease progression
55 F	MM (Y)	Ipilimumab	2	Cholestatic	Yes	Disease progression with widespread liver metastases (N)	Died of disease progression
59 M	MM (Y)	Ipilimumab	4	Cholestatic	No	Disease progression with widespread liver metastases (N)	Died of disease progression
73 F	RCC (N)	Nivolumab	14	Cholestatic	No	DILI (Y)	Nivolumab was restarted with no elevation in liver enzymes
75 M	MM (N)	Adjuvant Pembrolizumab	1	Cholestatic	Yes	Disease progression with widespread liver metastases (N)	Died of disease progression
63 M	MM (N)	Adjuvant Pembrolizumab	1	Mixed	Yes	Disease progression with widespread liver metastases (N)	Died of disease progression
75 F	MM (N)	Pembrolizumab	9	Cholestatic	Yes	Cholangitis/biliary obstruction (Y)	Pembrolizumab was restarted with no elevation in liver enzymes
69 M	MM (Y)	Ipilimumab + Nivolumab	1	Cholestatic	Yes	Disease progression with widespread liver metastases (N)	Died of disease progression
62 M	MM (Y)	Ipilimumab + Nivolumab	1	Hepatocellular	Yes	Disease progression with widespread liver metastases (N)	Died of disease progression
76 F	MM (Y)	Ipilimumab + Nivolumab	1	Mixed	Yes	Disease progression with widespread liver metastases (N)	Died of disease progression

Abbreviations: ChILI, Checkpoint inhibitor-induced liver injury; CPI, Checkpoint inhibitors; DILI, Idiosyncratic drug-induced liver injury; MM, Malignant Melanoma; RCC, Renal Cell Carcinoma

Figures

Figure 2. Risk of ChILI per CPI regime in melanoma and renal cancer




Figure 3. Probability of ChILI per CPI class over 1 year





Figure 3. Pattern and severity of ChILI cases from three centres



References

Author names in bold designate shared co-first authorship

1. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. *New England Journal of Medicine*. 2015;372(26):2521-32.
2. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. *N Engl J Med*. 2015;373(1):23-34.
3. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. *New England Journal of Medicine*. 2018;378(14):1277-90.
4. De Martin E, Michot JM, Rosmorduc O, Guettier C, Samuel D. Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. *JHEP Rep*. 2020;2(6):100170.
5. Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. *Nature Reviews Clinical Oncology*. 2019;16(9):563-80.
6. Björnsson ES, Stephens C, Atallah E, Robles-Diaz M, Alvarez-Alvarez I, Gerbes A, et al. A new framework for advancing in drug-induced liver injury research. The Prospective European DILI Registry. *Liver International*. 2023;43(1):115-26.
7. Clinton JW, Kiparizoska S, Aggarwal S, Woo S, Davis W, Lewis JH. Drug-Induced Liver Injury: Highlights and Controversies in the Recent Literature. *Drug Safety*. 2021;44(11):1125-49.
8. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0: National Cancer Institute; 2017 [78]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.
9. Zheng C, Huang S, Lin M, Hong B, Ni R, Dai H, et al. Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known. *Hepatology Communications*. 2023;7(3):e0063.
10. Yu Y, Ruddy KJ, Tsuji S, Hong N, Liu H, Shah N, et al. Coverage Evaluation of CTCAE for Capturing the Immune-related Adverse Events Leveraging Text Mining Technologies. *AMIA Joint Summits on Translational Science proceedings AMIA Joint Summits on Translational Science*. 2019;2019:771-8.
11. Tsung I, Dolan R, Lao CD, Fecher L, Riggerbach K, Yeboah-Korang A, et al. Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy. *Alimentary Pharmacology & Therapeutics*. 2019;50(7):800-8.
12. Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case definition and phenotype standardization in drug-induced liver injury. *Clin Pharmacol Ther*. 2011;89(6):806-15.
13. Peeraphatdit T, Wang J, Odenwald MA, Hu S, Hart J, Charlton MR. Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation. *Hepatology*. 2020;72(1):315-29.
14. Arnaud-Coffin P, Maillet D, Gan HK, Stelmes J-J, You B, Dalle S, et al. A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors. *International Journal of Cancer*. 2019;145(3):639-48.
15. Parlati L, Vallet-Pichard A, Batista R, Hernvann A, Sogni P, Pol S, et al. Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: A retrospective study. *Journal of Hepatology*. 2018;69(6):1396-7.
16. Smith MK, Chan Y, Suo AE, Shaheen AA, Congly SE, Tandon P, et al. Clinical Course and Treatment Implications of Combination Immune Checkpoint Inhibitor-Mediated

- Hepatitis: A Multicentre Cohort. *Journal of the Canadian Association of Gastroenterology*. 2021;5(1):39-47.
17. Biewenga M, van der Kooij MK, Wouters MWJM, Aarts MJB, van den Berkmortel FWPJ, de Groot JWB, et al. Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients. *Hepatology International*. 2021;15(2):510-9.
 18. Lee PY, Oen KQX, Lim GRS, Hartono JL, Muthiah M, Huang DQ, et al. Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study. *Cancers*. 2021;13(6):1308.
 19. Matsukane R, Watanabe H, Minami H, Hata K, Suetsugu K, Tsuji T, et al. Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events. *Scientific Reports*. 2021;11(1):1324.
 20. Unger JM, Vaidya R, Albain KS, LeBlanc M, Minasian LM, Gotay CC, et al. Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials. *Journal of Clinical Oncology*. 2022;40(13):1474-86.
 21. **Miah A, Tinoco G**, Zhao S, Wei L, Johns A, Patel S, et al. Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival. *Journal of Cancer Research and Clinical Oncology*. 2022.
 22. Zimmerman HJ. The spectrum of hepatotoxicity. *Perspectives in biology and medicine*. 1968;12(1):135-61.
 23. Danan G, Teschke R. RUCAM in Drug and Herb Induced Liver Injury: The Update. *Int J Mol Sci*. 2015;17(1).
 24. Wilson EB. Probable Inference, the Law of Succession, and Statistical Inference. *Journal of the American Statistical Association*. 1927;22(158):209-12.
 25. Altman D G MD, Bryant T N, Gardner M J (eds). *Statistics with confidence: Confidence intervals and statistical guidelines*. Second edition ed. Bristol: BMJ Books2000.
 26. Centanni M, Moes DJAR, Trocóniz IF, Ciccolini J, van Hasselt JGC. Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors. *Clinical Pharmacokinetics*. 2019;58(7):835-57.
 27. Armitage P, Berry G. *Statistical methods in medical research*. 3rd ed. ed. Oxford ;: Blackwell Scientific Publications; 1994.
 28. Breslow NE, Day NE. *Statistical methods in cancer research. Volume II--The design and analysis of cohort studies*. IARC scientific publications. 1987(82):1-406.
 29. R Core Team; *R: A Language and Environment for Statistical Computing*. 2020.
 30. Terry M. Therneau PMG. *Modeling Survival Data: Extending the Cox Model*. New York: Springer; 2000.
 31. Allignol A SM, Beyersmann J. Empirical Transition Matrix of Multi-State Models: The etm Package. *Journal of Statistical Software*2011. Available from: <https://www.jstatsoft.org/v38/i04/>.
 32. Gray B. cmprsk: Subdistribution Analysis of Competing Risks. R package version 2.2-112022.
 33. Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. *The Lancet Oncology*. 2019;20(10):1370-85.
 34. Suzuki A, Tillmann H, Williams J, Hauser RG, Frund J, Suzuki M, et al. Assessment of the Frequency, Phenotypes, and Outcomes of Acute Liver Injury Associated with Amoxicillin/Clavulanate in 1.4 Million Patients in the Veterans Health Administration. *Drug Safety*. 2023;46(2):129-43.
 35. Kaliyaperumal K, Grove JI, Delahay RM, Griffiths WJH, Duckworth A, Aithal GP. Pharmacogenomics of drug-induced liver injury (DILI): Molecular biology to clinical applications. *J Hepatol*. 2018;69(4):948-57.

36. Astbury S, Atallah E, Bozward A, Krajewska N, Wootton G, Grove JI, et al. Tu1291: Mass cytometry identifies a discrete population of effector memory CD8 T cells as a hallmark of liver injury due to immune checkpoint inhibitors. *Gastroenterology*. 2022;162(7, Supplement):S-1263.
37. Groha S, Alaiwi SA, Xu W, Naranbhai V, Nassar AH, Bakouny Z, et al. Germline variants associated with toxicity to immune checkpoint blockade. *Nature Medicine*. 2022;28(12):2584-91.
38. Özdemir BC, Csajka C, Dotto G-P, Wagner AD. Sex Differences in Efficacy and Toxicity of Systemic Treatments: An Undervalued Issue in the Era of Precision Oncology. *Journal of Clinical Oncology*. 2018;36(26):2680-3.
39. **Jiang F, Yan H, Liang L**, Du J, Jin S, Yang S, et al. Incidence and risk factors of anti-tuberculosis drug induced liver injury (DILI): Large cohort study involving 4652 Chinese adult tuberculosis patients. *Liver International*. 2021;41(7):1565-75.
40. Xu Q, Lu Z, Zhang X. A novel role of alkaline phosphatase in protection from immunological liver injury in mice. *Liver*. 2002;22(1):8-14.
41. Wu H, Wang Y, Yao Q, Fan L, Meng L, Zheng N, et al. Alkaline phosphatase attenuates LPS-induced liver injury by regulating the miR-146a-related inflammatory pathway. *International Immunopharmacology*. 2021;101:108149.
42. Rader BA. Alkaline Phosphatase, an Unconventional Immune Protein. *Front Immunol*. 2017;8:897.
43. **Andrews MC, Duong CPM, Gopalakrishnan V, Iebba V, Chen W-S, Derosa L**, et al. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. *Nature Medicine*. 2021;27(8):1432-41.
44. Betof AS, Nipp RD, Giobbie-Hurder A, Johnpulle RAN, Rubin K, Rubinstein SM, et al. Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma. *The Oncologist*. 2017;22(8):963-71.
45. Cunningham M, Iafolla M, Kanjanapan Y, Cerocchi O, Butler M, Siu LL, et al. Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy. *PLOS ONE*. 2021;16(6):e0253070.
46. Riveiro-Barciela M, Barreira-Díaz A, Vidal-González J, Muñoz-Couselo E, Martínez-Valle F, Viladomiu L, et al. Immune-related hepatitis related to checkpoint inhibitors: Clinical and prognostic factors. *Liver International*. 2020;40(8):1906-16.
47. Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Annals of Oncology*. 2022;33(12):1217-38.
48. Grover S, Rahma OE, Hashemi N, Lim RM. Gastrointestinal and Hepatic Toxicities of Checkpoint Inhibitors: Algorithms for Management. *American Society of Clinical Oncology Educational Book*. 2018(38):13-9.
49. De Martin E, Michot JM, Papouin B, Champiat S, Mateus C, Lambotte O, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. *J Hepatol*. 2018;68(6):1181-90.
50. Miller ED, Abu-Sbeih H, Styskel B, Nogueras Gonzalez GM, Blechacz B, Naing A, et al. Clinical Characteristics and Adverse Impact of Hepatotoxicity due to Immune Checkpoint Inhibitors. *Official journal of the American College of Gastroenterology | ACG*. 2020;115(2):251-61.
51. Del Castillo M, Romero FA, Argüello E, Kyi C, Postow MA, Redelman-Sidi G. The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma. *Clinical Infectious Diseases*. 2016;63(11):1490-3.
52. Aldea M, Orillard E, Mansi L, Marabelle A, Scotte F, Lambotte O, et al. How to manage patients with corticosteroids in oncology in the era of immunotherapy? *European Journal of Cancer*. 2020;141:239-51.
53. Coelho J, Ozenne V, Dray X, Chaput U, Marteau P. Case of Prednisolone-induced Hepatitis in a Patient with Ulcerative Colitis. *Inflammatory Bowel Diseases*. 2012;19(3):E34-E5.

54. Kajiwara A, Kawamura Y, Kinowaki K, Muraishi N, Iritani S, Akuta N, et al. A case of drug-induced acute liver failure caused by corticosteroids. *Clinical Journal of Gastroenterology*. 2022;15(5):946-52.
55. Lee C-C, Peng Y-J, Lu C-C, Chen H-C, Yeh F-C. Corticosteroid-Induced Liver Injury in Adult-Onset Still's Disease. *Medicina*. 2022;58(2):191.
56. Zoubek ME, Pinazo-Bandera J, Ortega-Alonso A, Hernández N, Crespo J, Contreras F, et al. Liver injury after methylprednisolone pulses: A disputable cause of hepatotoxicity. A case series and literature review. *United European Gastroenterology Journal*. 2019;7(6):825-37.
57. Haanen J, Ernstoff M, Wang Y, Menzies A, Puzanov I, Grivas P, et al. Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. *Journal for ImmunoTherapy of Cancer*. 2020;8(1):e000604.
58. Couey MA, Bell RB, Patel AA, Romba MC, Crittenden MR, Curti BD, et al. Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. *Journal for ImmunoTherapy of Cancer*. 2019;7(1):165.